All In Biotech

Drug Trial Radar · NCT07139535

A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of RAY1225 Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone

Last checked: Nov 19, 2026Latest source record: Aug 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

350

Planned (sponsor's estimate)

Start

Aug 31, 2025

Primary completion

Dec 1, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
Aug 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal for this study is to evaluate the efficacy and safety of RAY1225 versus placebo in participants with type 2 diabetes not under control with diet and exercise alone.

Conditions

  • T2DM

Interventions

  • RAY1225Drug

    Administered SC

  • placeboDrug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Hemoglobin A1c (HbA1c)Time frame: Baseline,36 Week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijingcun, Hebei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.